Laurus Labs share price today

Laurus Labs Ltd's share price was ₹2,323.80 at the close on 4 November 2026. It has been rising for 148 weeks. That is 49.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹930 and ₹2,406, and at that close it sat 94% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Laurus Labs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 46 weeks in a row.

Over the last 9.9 years the share price moved +2,343% while the NIFTY 500 moved +220%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: best operating margin in 16 quarters, revenue up on a year earlier for 8 quarters in a row and profit up on a year earlier for 8 quarters in a row.

1. Best operating margin in 16 quarters

   Operating margin was 34% in the September 2026 quarter, against 24% a year earlier.

   Why: The share of sales left as operating profit rose because more of the sales came from higher-margin products and the company ran its operations more efficiently.

   Next results: check whether the company keeps its gross margin above 60% and its EBITDA margin, a measure of operating profit, above 30%.

   From the earnings call on 29 Oct 2026.

2. Revenue up on a year earlier for 8 quarters in a row

   In the September 2026 quarter revenue was ₹2,206 crore, +33.5% on a year earlier.

   Why: Revenue rose because the company made much more medicine for other drug companies.

   Next results: check whether sales of medicine made for other drug companies hold up without customers running down their stock and the profit margin stays intact.

   From the earnings call on 29 Oct 2026.

3. Profit up on a year earlier for 8 quarters in a row

   In the September 2026 quarter profit was ₹436 crore, +124.7% on a year earlier.

   Why: Profit rose much faster than sales because more of the sales came from higher-margin products and the company ran its operations more efficiently.

   Next results: check whether gross margin stays above 60% and EBITDA margin, a measure of operating profit, stays above 30%.

   From the earnings call on 29 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Laurus Labs reported revenue of ₹2,206 crore, up 33.5% from ₹1,653 crore a year earlier, and a profit of ₹436 crore, up 124.7% from ₹194 crore.

Laurus Labs results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Laurus Labs' management discussed these results on a call held on 29 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Laurus Labs closed at ₹2,323.80 on 4 November 2026, up 136.6% from ₹982.15 a year earlier (7 November 2025) and up 366.2% over five years. Its highest weekly close since December 2016 was ₹2,405.50 on 30 October 2026.

Laurus Labs share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

523 weekly closes from 23 December 2016 to 4 November 2026.

6 Nov 2026: Coming up: ex-date for an interim dividend of ₹1 a share. 4 Nov 2026: Laurus Labs closed at ₹2,323.80, down 3.4% on the week and up 17.1% on the month.

Earlier

• 29 Oct 2026: Laurus Labs held its results call for July to September 2026. Management guided: Gross margin above 60% and operating margin above 30% going forward.
• Results for July to September 2026: Revenue up 33.5% and profit up 124.7% on a year earlier.
• 8 May 2026: ex-date for an interim dividend of ₹1.20 a share.

Laurus Labs paid ₹1.20 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.05% at the ₹2,323.80 close on 4 November 2026. The last was an interim dividend of ₹1.20 a share, ex-date 8 May 2026. Next: ₹1 a share, ex-date 6 November 2026.

Laurus Labs dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Laurus Labs Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 29 October 2026, Laurus Labs' management guided: Gross margin above 60% and operating margin above 30% going forward.

“Today, if any partner comes with a tech pack, we will not say no because we do not have the capabilities, except for monoclonal antibodies, cephalosporins, and penicillins. Those are the areas we do not have right now.”Dr Satyanarayana Chava, on the call for July to September 2026

What management guided

• Peptide validation batches to begin in 12-18 months on commercial-scale block.
• Peptide commercial revenues from current capacities around 2029 with high validation utilization.
• LB-4 fermentation operational by end-2026 and KRKA JV Phase-1 blocks from mid-2027 with revenues in 2028-2029.
• Capital spending ₹2,000 crore each in 2027 and 2028 then around ₹1,500 crore annually thereafter.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 29 October 2026.

When Laurus Labs reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Peptide validation campaigns to commence on commercial block with high utilization - check start and scale per flagged window.

Laurus Labs is on 3 of our India lists: Momentum stocks, 52 week high & low and Pharma stocks.

Laurus Labs Ltd earned ₹436 Cr of net profit in the Sep 2026 quarter, +124.7% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹890 Cr. Over 10 years profit has grown 20.8% a year on average. That is 19.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹194 Cr.

For the full year, FY26 profit was ₹890 Cr (+148.6% on the year before).

Why profit moved: revenue changed +33.5% on a year earlier and the margin moved +10.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +110.0% and revenue +23.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Laurus Labs Ltd reported ₹2,206 Cr of revenue in the Sep 2026 quarter, +33.5% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 14.4% a year on average. The last full year, FY26, came in at ₹6,813 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹7,822 Cr.

FY26 revenue was ₹6,813 Cr, +22.7% on the year before.

Recent pace: the last four quarters grew +23.4% on average, against 14.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +23.0%, against +24.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +95.3%, against +218.9% a year (rolling over).

Laurus Labs Ltd's operating margin was 34.0% in the Sep 2026 quarter, 10.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 15.0% and 32.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +9.6 percentage points on the year while gross margin changed +3.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 205% of Laurus Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,624 Cr of operating cash against ₹890 Cr of profit. After ₹1,043 Cr of spending on assets, ₹581 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 205% of profit came in as cash: the cash cycle got 97 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building.

Laurus Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 166 days in FY21. It spent ₹2,479 Cr on assets over the last 3 years. Customers take 115 days to pay, and stock sits for 317 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹6,813 Cr, each day of that cycle ties up about ₹18.7 Cr, so roughly ₹4,909 Cr is tied up in the business at any time.

FY26: customers took 115 days to pay and stock sat for 317 days, about 10.4 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 166.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 317 days. Customers pay about 115 days after that. Suppliers are paid at 170 days. Together that makes the 263-day cycle.

Spending on assets: ₹2,479 Cr over the last 3 years, against ₹1,295 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹773 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Laurus Labs Ltd's P/E is 93.7×, near the high end of its own history: higher than 84% of past readings. Its usual P/E (the middle reading) is 35.5×, over 9.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.